Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval

Stock Track

08/07

Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.

The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.

The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1151684334"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151684334\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151684334?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151684334","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1151684334","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151684334","pubTimestamp":1786113661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票追踪|Moderna盘中飙升5.28%，首个mRNA流感疫苗获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}